Lisa Kojima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lisa Kojima has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Kazunari Sasaki
Stanford Transplant Outcomes Research Center (STORC), Division of Abdominal Transplantation, Stanford University Medical Center, Stanford, California
3 shared publications - Heidi Yeh
Division of Transplant Surgery, Massachusetts General Hospital, Boston, MA
2 shared publications - James F. Markmann
Transplant Surgery, Penn Medicine, University of Pennsylvania, Philadelphia, PA
2 shared publications - Miho Akabane
Division of Abdominal Transplant, Department of Surgery Stanford University School of Medicine Stanford California USA
2 shared publications - Shoko Kimura
Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA
2 shared publications Abigail Snyder
Department of Hepato-pancreato-biliary & Liver Transplant Surgery, Digestive Diseases and Surgery Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA
1 shared publication
Latest Publications
- 23 August 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (3) , 344-354
Reappraisal of tacrolimus levels after liver transplant for HCC: A multicenter study toward personalized immunosuppression regimen
Post-liver transplant (LT) immunosuppression is necessary to prevent rejection; however, a major consequence of this is tumor recurrence. Although recurrence is a concern after LT for patients with HCC, the oncologically optimal tacrolimus (FK) regimen is still unknown. This retrospective study included 1406 patients with HCC who underwent LT (2002–2019) at 4 US institutions using variable post-LT immunosuppression regimens. Receiver operating characteristic analyses were performed to investigate the influences of post-LT time-weighted average FK (TWA-FK) level on HCC recurrence. A competing risk analysis was employed to evaluate the prognostic influence of TWA-FK while adjusting for patient and tumor characteristics. The AUC for TWA-FK was greatest at 2 weeks (0.68), followed by 1 week (0.64) after LT. Importantly, this was consistently observed across the institutions despite immunosuppression regimen variability. In addition, the TWA-FK at 2 weeks was not associated with rejection within 6 months of LT. A competing risk regression analysis showed that TWA-FK at 2 weeks after LT is significantly associated with recurrence (HR: 1.31, 95% CI: 1.21–1.41, p < 0.001). The TWA-FK effect on recurrence varied depending on the exposure level and the individual’s risk of recurrence, including vascular invasion and tumor morphology. Although previous studies have explored the influence of FK levels at 1–3 months after LT on HCC recurrence, this current study suggests that earlier time points and exposure levels must be evaluated. Each patient’s oncological risk must also be considered in developing an individualized immunosuppression regimen.
- 23 August 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (3) , 344-354
Reappraisal of tacrolimus levels after liver transplant for HCC: A multicenter study toward personalized immunosuppression regimen
Post-liver transplant (LT) immunosuppression is necessary to prevent rejection; however, a major consequence of this is tumor recurrence. Although recurrence is a concern after LT for patients with HCC, the oncologically optimal tacrolimus (FK) regimen is still unknown. This retrospective study included 1406 patients with HCC who underwent LT (2002–2019) at 4 US institutions using variable post-LT immunosuppression regimens. Receiver operating characteristic analyses were performed to investigate the influences of post-LT time-weighted average FK (TWA-FK) level on HCC recurrence. A competing risk analysis was employed to evaluate the prognostic influence of TWA-FK while adjusting for patient and tumor characteristics. The AUC for TWA-FK was greatest at 2 weeks (0.68), followed by 1 week (0.64) after LT. Importantly, this was consistently observed across the institutions despite immunosuppression regimen variability. In addition, the TWA-FK at 2 weeks was not associated with rejection within 6 months of LT. A competing risk regression analysis showed that TWA-FK at 2 weeks after LT is significantly associated with recurrence (HR: 1.31, 95% CI: 1.21–1.41, p < 0.001). The TWA-FK effect on recurrence varied depending on the exposure level and the individual’s risk of recurrence, including vascular invasion and tumor morphology. Although previous studies have explored the influence of FK levels at 1–3 months after LT on HCC recurrence, this current study suggests that earlier time points and exposure levels must be evaluated. Each patient’s oncological risk must also be considered in developing an individualized immunosuppression regimen.
- 11 April 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (8) , e14989
Impact of donor sex on hepatocellular carcinoma recurrence in liver transplantation after brain death
Background: Hepatocellular carcinoma (HCC) is predominantly seen in males but has a better prognosis in females. No prior studies have investigated HCC recurrence based on sex combination following liver transplant donated after brain death (DBDLT). This study sought to elucidate the effects of donor and recipient sex on HCC recurrence rates.Methods: 9232 adult recipients from the United Network for Organ Sharing (UNOS) database who underwent DBDLT for HCC from 2012 to 2018 were included. Donor‐recipient pairs were divided into (1) female donor/female recipient (F‐F) (n = 1089); (2) male donor/female recipient (M‐F) (n = 975); (3) female donor/male recipient (F‐M) (n = 2691); (4) male donor/male recipient (M‐M) (n = 4477). The primary prognostic outcome was HCC recurrence. A multivariable competing risk regression analysis was used to assess prognostic influences.Results: The median recipient age and model for end‐stage liver disease (MELD) scores were similar among the four groups. Livers of male recipients demonstrated greater in size and number of HCC (both p‐values were <.0001). There was also a higher rate of vascular invasion in male recipients compared to female (p < .0001). Competing risk analyses showed that the cumulative HCC recurrence rate was significantly lower in the M‐F group (p = .013). After adjusting for tumor characteristics, liver grafts from male donors were associated with a lower HCC recurrence rate in female recipients (HR: .62 95%CI: .42‐.93) (p = .021).Conclusion: In DBDLT, male donor to female recipient pairing exhibited lower HCC recurrence rates.Summary: Lowest rates of HCC recurrence were confirmed among the female recipients of male donor grafts group in the deceased donor LT cohort. A competing risk multivariable regression analysis demonstrated that male donor sex was significantly associated with low HCC recurrence in female but not male recipients.
- 11 April 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (8) , e14989
Impact of donor sex on hepatocellular carcinoma recurrence in liver transplantation after brain death
Background: Hepatocellular carcinoma (HCC) is predominantly seen in males but has a better prognosis in females. No prior studies have investigated HCC recurrence based on sex combination following liver transplant donated after brain death (DBDLT). This study sought to elucidate the effects of donor and recipient sex on HCC recurrence rates.Methods: 9232 adult recipients from the United Network for Organ Sharing (UNOS) database who underwent DBDLT for HCC from 2012 to 2018 were included. Donor‐recipient pairs were divided into (1) female donor/female recipient (F‐F) (n = 1089); (2) male donor/female recipient (M‐F) (n = 975); (3) female donor/male recipient (F‐M) (n = 2691); (4) male donor/male recipient (M‐M) (n = 4477). The primary prognostic outcome was HCC recurrence. A multivariable competing risk regression analysis was used to assess prognostic influences.Results: The median recipient age and model for end‐stage liver disease (MELD) scores were similar among the four groups. Livers of male recipients demonstrated greater in size and number of HCC (both p‐values were <.0001). There was also a higher rate of vascular invasion in male recipients compared to female (p < .0001). Competing risk analyses showed that the cumulative HCC recurrence rate was significantly lower in the M‐F group (p = .013). After adjusting for tumor characteristics, liver grafts from male donors were associated with a lower HCC recurrence rate in female recipients (HR: .62 95%CI: .42‐.93) (p = .021).Conclusion: In DBDLT, male donor to female recipient pairing exhibited lower HCC recurrence rates.Summary: Lowest rates of HCC recurrence were confirmed among the female recipients of male donor grafts group in the deceased donor LT cohort. A competing risk multivariable regression analysis demonstrated that male donor sex was significantly associated with low HCC recurrence in female but not male recipients.
- 28 February 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 29 (8) , 793-803
Evaluating the outcomes of donor-recipient age differences in young adults undergoing liver transplantation
The current liver allocation system may be disadvantaging younger adult recipients as it does not incorporate the donor-recipient age difference. Given the longer life expectancy of younger recipients, the influences of older donor grafts on their long-term prognosis should be elucidated. This study sought to reveal the long-term prognostic influence of the donor-recipient age difference in young adult recipients. Adult patients who received initial liver transplants from deceased donors between 2002 and 2021 were identified from the UNOS database. Young recipients (patients 45 years old or below) were categorized into 4 groups: donor age younger than the recipient, 0–9 years older, 10–19 years older, or 20 years older or above. Older recipients were defined as patients 65 years old or above. To examine the influence of the age difference in long-term survivors, conditional graft survival analysis was conducted on both younger and older recipients. Among 91,952 transplant recipients, 15,170 patients were 45 years old or below (16.5%); these were categorized into 6,114 (40.3%), 3,315 (21.9%), 2,970 (19.6%), and 2,771 (18.3%) for groups 1–4, respectively. Group 1 demonstrated the highest probability of survival, followed by groups 2, 3, and 4 for the actual graft survival and conditional graft survival analyses. In younger recipients who survived at least 5 years post-transplant, inferior long-term survival was observed when there was an age difference of 10 years or above (86.9% vs. 80.6%, log-rank pp=0.89). In younger patients who are not in emergent need of a transplant, preferential allocation of younger aged donor offers would optimize organ utility by increasing postoperative graft survival time.
- 28 February 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 29 (8) , 793-803
Evaluating the outcomes of donor-recipient age differences in young adults undergoing liver transplantation
The current liver allocation system may be disadvantaging younger adult recipients as it does not incorporate the donor-recipient age difference. Given the longer life expectancy of younger recipients, the influences of older donor grafts on their long-term prognosis should be elucidated. This study sought to reveal the long-term prognostic influence of the donor-recipient age difference in young adult recipients. Adult patients who received initial liver transplants from deceased donors between 2002 and 2021 were identified from the UNOS database. Young recipients (patients 45 years old or below) were categorized into 4 groups: donor age younger than the recipient, 0–9 years older, 10–19 years older, or 20 years older or above. Older recipients were defined as patients 65 years old or above. To examine the influence of the age difference in long-term survivors, conditional graft survival analysis was conducted on both younger and older recipients. Among 91,952 transplant recipients, 15,170 patients were 45 years old or below (16.5%); these were categorized into 6,114 (40.3%), 3,315 (21.9%), 2,970 (19.6%), and 2,771 (18.3%) for groups 1–4, respectively. Group 1 demonstrated the highest probability of survival, followed by groups 2, 3, and 4 for the actual graft survival and conditional graft survival analyses. In younger recipients who survived at least 5 years post-transplant, inferior long-term survival was observed when there was an age difference of 10 years or above (86.9% vs. 80.6%, log-rank pp=0.89). In younger patients who are not in emergent need of a transplant, preferential allocation of younger aged donor offers would optimize organ utility by increasing postoperative graft survival time.
- Open Access
- 8 September 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (17)
Suppression of allograft rejection by regulatory B cells induced via TLR signaling
B lymphocytes have long been recognized for their critical contributions to adaptive immunity, providing defense against pathogens through cognate antigen presentation to T cells and Ab production. More recently appreciated is that B cells are also integral in securing self-tolerance; this has led to interest in their therapeutic application to downregulate unwanted immune responses, such as transplant rejection. In this study, we found that PMA- and ionomycin-activated mouse B cells acquire regulatory properties following stimulation through TLR4/TLR9 receptors (Bregs-TLR). Bregs-TLR efficiently inhibited T cell proliferation in vitro and prevented allograft rejection. Unlike most reported Breg activities, the inhibition of alloimmune responses by Bregs-TLR relied on the expression of TGF-β and not IL-10. In vivo, Bregs-TLR interrupted donor-specific T cell expansion and induced Tregs in a TGF-β–dependent manner. RNA-Seq analyses corroborated the involvement of TGF-β pathways in Breg-TLR function, identified potential gene pathways implicated in preventing graft rejection, and suggested targets to foster Breg regulation.
- 8 September 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (17)
Open AccessSuppression of allograft rejection by regulatory B cells induced via TLR signaling
B lymphocytes have long been recognized for their critical contributions to adaptive immunity, providing defense against pathogens through cognate antigen presentation to T cells and Ab production. More recently appreciated is that B cells are also integral in securing self-tolerance; this has led to interest in their therapeutic application to downregulate unwanted immune responses, such as transplant rejection. In this study, we found that PMA- and ionomycin-activated mouse B cells acquire regulatory properties following stimulation through TLR4/TLR9 receptors (Bregs-TLR). Bregs-TLR efficiently inhibited T cell proliferation in vitro and prevented allograft rejection. Unlike most reported Breg activities, the inhibition of alloimmune responses by Bregs-TLR relied on the expression of TGF-β and not IL-10. In vivo, Bregs-TLR interrupted donor-specific T cell expansion and induced Tregs in a TGF-β–dependent manner. RNA-Seq analyses corroborated the involvement of TGF-β pathways in Breg-TLR function, identified potential gene pathways implicated in preventing graft rejection, and suggested targets to foster Breg regulation.
- 6 September 2022
- Published by Elsevier in Journal of Surgical Education
- Vol. 79 (6) , e220-e224
The Patient's Voice in Assessing Resident Communication Skills
- 6 September 2022
- Published by Elsevier in Journal of Surgical Education
- Vol. 79 (6) , e220-e224
The Patient's Voice in Assessing Resident Communication Skills